| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$41,361 ) |
| | 2025 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 001 | 3 | NIH | 3/13/2025 | -$35,491 |
| | 2025 | 2021 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 000 | 2 | NIH | 3/13/2025 | -$5,870 |
|
| Issue Date FY: 2024 ( Subtotal = -$337 ) |
| | 2024 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01NS107569 | Targeting GPR109A for the treatment of pain in systemic lupus erythematosus | 000 | 6 | NIH | 6/13/2024 | $0 |
| | 2024 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL144590 | Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients | 000 | 4 | NIH | 2/16/2024 | $0 |
| | 2024 | 2020 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R21CA231111 | Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data | 000 | 3 | NIH | 2/5/2024 | -$337 |
|
| Issue Date FY: 2023 ( Subtotal = -$566,930 ) |
| | 2023 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01NS107569 | Targeting GPR109A for the treatment of pain in systemic lupus erythematosus | 001 | 6 | NIH | 11/19/2022 | $149,215 |
| | 2023 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 000 | 3 | NIH | 2/15/2023 | -$716,145 |
|
| Issue Date FY: 2022 ( Subtotal = $1,548,434 ) |
| | 2022 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL144590 | Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients | 000 | 4 | NIH | 2/4/2022 | $325,485 |
| | 2022 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL144590 | Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients | 001 | 4 | NIH | 6/14/2022 | $36,167 |
| | 2022 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 003 | 3 | NIH | 9/15/2022 | $751,636 |
| | 2022 | 2022 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01NS107569 | Targeting GPR109A for the treatment of pain in systemic lupus erythematosus | 001 | 6 | NIH | 9/15/2022 | $435,185 |
| | 2022 | 2021 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 001 | 2 | NIH | 8/5/2022 | $0 |
| | 2022 | 2021 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 002 | 2 | NIH | 8/10/2022 | $0 |
| | 2022 | 2020 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 000 | 1 | NIH | 8/5/2022 | $0 |
| | 2022 | 2020 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R21CA231111 | Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data | 000 | 3 | NIH | 8/31/2022 | $0 |
| | 2022 | 2018 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL114677 | Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH | 000 | 5 | NIH | 2/14/2022 | -$39 |
|
| Issue Date FY: 2021 ( Subtotal = $1,720,261 ) |
| | 2021 | 2021 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL144590 | Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients | 004 | 3 | NIH | 7/1/2021 | $699,954 |
| | 2021 | 2021 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 000 | 2 | NIH | 8/20/2021 | $703,339 |
| | 2021 | 2021 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL144590 | Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients | 001 | 3 | NIH | 3/16/2021 | $365,632 |
| | 2021 | 2018 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL114677 | Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH | 003 | 5 | NIH | 7/16/2021 | $38 |
| | 2021 | 2018 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL114677 | Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH | 001 | 5 | NIH | 3/16/2021 | $45,677 |
| | 2021 | 2016 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R15CA202757 | Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities | 001 | 1 | NIH | 7/29/2021 | -$94,378 |
| | 2021 | 2016 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R15CA202757 | Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities | 000 | 1 | NIH | 12/21/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,128,522 ) |
| | 2020 | 2020 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R21CA231111 | Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data | 004 | 3 | NIH | 8/21/2020 | $68,738 |
| | 2020 | 2020 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R01HL139639 | Gestational Hyperandrogenism in Cardiovascular Programming | 000 | 1 | NIH | 9/7/2020 | $743,522 |
| | 2020 | 2019 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R21CA231111 | Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data | 003 | 2 | NIH | 8/11/2020 | $133,562 |
| | 2020 | 2019 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R21CA231111 | Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data | 001 | 2 | NIH | 3/27/2020 | $182,700 |
| | 2020 | 2016 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R15CA202757 | Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities | 000 | 1 | NIH | 2/26/2020 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $421,195 ) |
| | 2016 | 2016 | CALIFORNIA NORTHSTATE UNIVERSITY, LLC | 9700 W TARON DR | ELK GROVE | CA | 95757-8145 | SACRAMENTO | USA | R15CA202757 | Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities | 000 | 1 | NIH | 6/13/2016 | $421,195 |
|
|
